Literature DB >> 15684378

Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction.

Suxia Bai1, Bin He, Elizabeth M Wilson.   

Abstract

Gene activation by steroid hormone receptors involves the recruitment of the steroid receptor coactivator (SRC)/p160 coactivator LXXLL motifs to activation function 2 (AF2) in the ligand binding domain. For the androgen receptor (AR), AF2 also serves as the interaction site for the AR NH(2)-terminal FXXLF motif in the androgen-dependent NH(2)-terminal and carboxyl-terminal (N/C) interaction. The relative importance of the AR AF2 site has been unclear, since the AR FXXLF motif interferes with coactivator recruitment by competitive inhibition of LXXLL motif binding. In this report, we identified the X chromosome-linked melanoma antigen gene product MAGE-11 as an AR coregulator that specifically binds the AR NH(2)-terminal FXXLF motif. Binding of MAGE-11 to the AR FXXLF alpha-helical region stabilizes the ligand-free AR and, in the presence of an agonist, increases exposure of AF2 to the recruitment and activation by the SRC/p160 coactivators. Intracellular association between AR and MAGE-11 is supported by their coimmunoprecipitation and colocalization in the absence and presence of hormone and by competitive inhibition of the N/C interaction. AR transactivation increases in response to MAGE-11 and the SRC/p160 coactivators through mechanisms that include but are not limited to the AF2 site. MAGE-11 is expressed in androgen-dependent tissues and in prostate cancer cell lines. The results suggest MAGE-11 is a unique AR coregulator that increases AR activity by modulating the AR interdomain interaction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15684378      PMCID: PMC548016          DOI: 10.1128/MCB.25.4.1238-1257.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  52 in total

1.  Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain.

Authors:  B He; J A Kemppainen; J J Voegel; H Gronemeyer; E M Wilson
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

2.  Androgen-induced NH2- and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2.

Authors:  B He; N T Bowen; J T Minges; E M Wilson
Journal:  J Biol Chem       Date:  2001-09-10       Impact factor: 5.157

Review 3.  Androgen receptor signaling in androgen-refractory prostate cancer.

Authors:  M E Grossmann; H Huang; D J Tindall
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

4.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

Authors:  C W Gregory; R T Johnson; J L Mohler; F S French; E M Wilson
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

5.  Domain interactions between coregulator ARA(70) and the androgen receptor (AR).

Authors:  Zhong-xun Zhou; Bin He; Susan H Hall; Elizabeth M Wilson; Frank S French
Journal:  Mol Endocrinol       Date:  2002-02

6.  Interaction of the tau2 transcriptional activation domain of glucocorticoid receptor with a novel steroid receptor coactivator, Hic-5, which localizes to both focal adhesions and the nuclear matrix.

Authors:  L Yang; J Guerrero; H Hong; D B DeFranco; M R Stallcup
Journal:  Mol Biol Cell       Date:  2000-06       Impact factor: 4.138

7.  FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor.

Authors:  B He; J A Kemppainen; E M Wilson
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

8.  Thyroid receptor activator molecule, TRAM-1, is an androgen receptor coactivator.

Authors:  J A Tan; S H Hall; P Petrusz; F S French
Journal:  Endocrinology       Date:  2000-09       Impact factor: 4.736

9.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.

Authors:  C W Gregory; B He; R T Johnson; O H Ford; J L Mohler; F S French; E M Wilson
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

10.  Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.

Authors:  S Yeh; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

View more
  64 in total

1.  Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-dependent transactivation.

Authors:  William H Lagarde; Amanda J Blackwelder; John T Minges; Andrew T Hnat; Frank S French; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

Review 2.  Cancer/testis antigens and urological malignancies.

Authors:  Prakash Kulkarni; Takumi Shiraishi; Krithika Rajagopalan; Robert Kim; Steven M Mooney; Robert H Getzenberg
Journal:  Nat Rev Urol       Date:  2012-06-19       Impact factor: 14.432

Review 3.  Small molecule inhibitors as probes for estrogen and androgen receptor action.

Authors:  David J Shapiro; Chengjian Mao; Milu T Cherian
Journal:  J Biol Chem       Date:  2010-12-13       Impact factor: 5.157

4.  The role of MAGEA2 in head and neck cancer.

Authors:  Chad A Glazer; Ian M Smith; Sheetal Bhan; Wenyue Sun; Steven S Chang; Kavita M Pattani; William Westra; Zubair Khan; Joseph A Califano
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2011-03

5.  Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.

Authors:  Adam R Karpf; Suxia Bai; Smitha R James; James L Mohler; Elizabeth M Wilson
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

6.  Androgen receptor regulation by histone methyltransferase Suppressor of variegation 3-9 homolog 2 and Melanoma antigen-A11.

Authors:  Emily B Askew; Suxia Bai; Amanda B Parris; John T Minges; Elizabeth M Wilson
Journal:  Mol Cell Endocrinol       Date:  2016-12-29       Impact factor: 4.102

7.  A novel function of caspase-8 in the regulation of androgen-receptor-driven gene expression.

Authors:  Wei Qi; Hong Wu; Lin Yang; Douglas D Boyd; Zhengxin Wang
Journal:  EMBO J       Date:  2006-12-14       Impact factor: 11.598

Review 8.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

9.  Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.

Authors:  Olga Aprelikova; Silvia Pandolfi; Sean Tackett; Mark Ferreira; Konstantin Salnikow; Yvona Ward; John I Risinger; J Carl Barrett; John Niederhuber
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

10.  Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis.

Authors:  Cheng-Lung Hsu; Jai-Shin Liu; Po-Long Wu; Hong-Hsiang Guan; Yuh-Ling Chen; An-Chi Lin; Huei-Ju Ting; See-Tong Pang; Shauh-Der Yeh; Wen-Lung Ma; Chung-Jung Chen; Wen-Guey Wu; Chawnshang Chang
Journal:  Mol Oncol       Date:  2014-06-24       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.